HCW Biologics Inc. (HCWB) |
|
2.0373 0.037 (1.87%)
|
02-03 13:41 |
|
Open: |
2.03 |
Pre. Close: |
2 |
|
High:
|
2.04 |
Low:
|
2.02 |
|
Volume:
|
5,308 |
Market Cap:
|
73(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 2:47:34 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 2.59  One year: 3.02 |
| Support: |
Support1: 1.96 Support2: 1.79 |
| Resistance: |
Resistance1: 2.22 Resistance2: 2.59 |
| Pivot: |
2.05  |
| Moving Average: |
MA(5): 1.98 MA(20): 2.05
MA(100): 2.15 MA(250): 2.26 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 21.1 %D(3): 12.3 |
| RSI: |
RSI(14): 49.6 |
| 52-week: |
High: 3.31 Low: 1.75 |
| Average Vol(K): |
3-Month: 20 (K) 10-Days: 13 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HCWB ] has closed above bottom band by 42.4%. Bollinger Bands are 9.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.02 - 2.03 |
2.03 - 2.04 |
|
Low:
|
1.98 - 1.99 |
1.99 - 2 |
|
Close:
|
1.98 - 2 |
2 - 2.02 |
|
Company Description |
|
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida. |
Headline News |
Mon, 02 Jan 2023
Organigram And Rounding Out My Tax Loss Selling Basket ... - Seeking Alpha
Thu, 08 Dec 2022
HCW Biologics Enters CRADA with National Cancer Institute - GlobeNewswire
Mon, 07 Nov 2022
Florida's Life Science Leaders United to Celebrate 25 Years of ... - PR Newswire
Mon, 07 Nov 2022
HCW Biologics Reports Third Quarter 2022 Financial Results And ... - GlobeNewswire
Fri, 12 Aug 2022
HCW Biologics Reports Second Quarter 2022 Financial Results And ... - GlobeNewswire
Wed, 03 Aug 2022
U.S. Patent Issued to HCW Biologics for Foundational Platform ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
36 (M) |
| Shares Float |
12 (M) |
|
% Held by Insiders
|
59.7 (%) |
|
% Held by Institutions
|
1.8 (%) |
|
Shares Short
|
24 (K) |
|
Shares Short P.Month
|
15 (K) |
Stock Financials |
|
EPS
|
-0.44 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.19 |
|
Profit Margin (%)
|
-235.3 |
|
Operating Margin (%)
|
-232.8 |
|
Return on Assets (ttm)
|
-14.6 |
|
Return on Equity (ttm)
|
-26.3 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0.14 |
|
EBITDA (p.s.)
|
-0.34 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-10 (M) |
|
Levered Free Cash Flow
|
-16 (M) |
Stock Valuations |
|
PE Ratio
|
-4.66 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.71 |
|
Price to Sales
|
13.58 |
|
Price to Cash Flow
|
-7.33 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
